Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy-Reference-Cited by-同舟云学术

Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy

Published:2020 Issue:1 Volume:24 Page:34-41
ISSN:1428-2526
Container-title:Współczesna Onkologia
language:
Short-container-title:wo

Author:

Cybulska-Stopa Bożena,Ługowska Iwona,Wiśniowski Rafał,Domagała-Haduch Małgorzata,Rajczykowski Marcin,Piejko Karolina,Bar-Letkiewicz Ilona,Suwiński Rafał,Regulski Krzysztof,Mackiewicz Jacek

Publisher

Termedia Sp. z.o.o.

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Visceral fat and clinical outcome in patients receiving first-line chemotherapy with bevacizumab for metastatic colorectal cancer;Clinics and Research in Hepatology and Gastroenterology;2024-08

2. The Role of Adipocytes Recruited as Part of Tumor Microenvironment in Promoting Colorectal Cancer Metastases;International Journal of Molecular Sciences;2024-07-30

3. Effect of body mass index on survival in patients with metastatic colorectal cancer receiving chemotherapy plus bevacizumab: a systematic review and meta-analysis;Frontiers in Nutrition;2024-07-16

4. Post‐diagnosis adiposity and colorectal cancer prognosis: A Global Cancer Update Programme (CUP Global) systematic literature review and meta‐analysis;International Journal of Cancer;2024-05

5. Pharmacokinetic considerations for angiogenesis inhibitors used to treat hepatocellular carcinoma: an overview;Expert Opinion on Drug Metabolism & Toxicology;2023-10-20